Background: Interstitial lung disease (ILD) includes a heterogeneous group of disorders that result in diffuse parenchymal lung disease, with overlapping clinical, radiographic, and physiologic manifestations. Several rheumatologic conditions are associated with the development of ILD. There are many patients who are not diagnosed as definite connective tissue disease (CTD). These patients may have an undifferentiated connective tissue disease (UCTD). Objectives: The aim of this study was to compare the prevalence and characteristics of patients with CTD-ILD, UCTD-ILD and Idiopathic pulmonary fibrosis (IPF) in Korean patients. Methods: We study compared the prevalence and characteristics of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD), undifferentiated connective tissue disease-associated interstitial lung disease (UCTD-ILD), or idiopathic pulmonary fibrosis (IPF) between January 2015 and June 2016 in Korea university guro hospital. Clinical characteristics, laboratory tests, and high-resolution CT images were analyzed and compared among three groups. Results: CTD-ILD was identified in 13.0%, UCTD-ILD in 18.2%, and IPF in 68.7% among 307 patients. Female and younger age patients were dominant in CTD-ILD group. Pulmonary symptoms were more common in IPF, while extra-pulmonary symptoms were more common in CTD-ILD and UCTD-ILD group. Patients with CTD-ILD had more abnormal antibody tests than those of UCTD-ILD and IPF. Usual interstitial pneumonia pattern was dominant in HRCT images among three groups. Conclusions: CTD-ILD is not able to be diagnosed accurately in ILD patients. A systematic evaluation of extra-pulmonary symptoms and serologic tests in patients with ILD can identify CTD-ILD, UCTD-ILD, and IPF. Background: Recently we found that use of allopurinol, the most commonly used urate-lowering therapy (ULT), was associated with a reduction of the risk of myocardial infarction and stroke, acute manifestations of CAD. Given that both PAD and CAD are manifestations of atherosclerosis and a similarity of disease pathophysiology between them, an obvious question was whether allopurinol use would reduce PAD. To our knowledge, no previous studies have examined whether allopurinol use reduces the risk of PAD. Objectives: To examine whether new allopurinol use is independently associated with a reduction of the risk of incident peripheral arterial disease (PAD) in the U.S. elderly. Methods: We used the 5% random Medicare sample from 2006-2012 to examine the association of allopurinol use and its duration with risk/hazard of incident PAD, in a retrospective cohort study. Multivariable Cox regression models adjusted for demographics, comorbidity, cardiac medications and cardiac conditions. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated. Results: We identified 26,985 episodes of incident allopurinol use in 25,282 beneficiaries, of which 3,167 allopurinol use episodes (12%) ended in incident PAD. In multivariable-adjusted analyses, allopurinol use was associated with HR of 0.88 (95% CI, 0.81, 0.95) for incident PAD, as was female gender, 0.84 (95% CI, 0.78, 0.90). In a separate multivariable-adjusted model, compared no allopurinol use, longer durations of allopurinol use were associated with lower HR of PAD: 181 days to 2 years, 0.88 (95% CI, 0.79, 0.97) and >2 years, 0.75 (95% CI, 0.63, 0.89). Other factors significantly associated with a higher hazard of PAD were age 75-<85 and ≥85, female gender, higher Charlson index score, and black race. Sensitivity analyses adjusting for cardiac conditions and medications, confirmed these findings with minimal to no attenuation of hazard ratios. Conclusions: New allopurinol use was independently associated with a lower risk of PAD in the elderly. Longer allopurinol use durations seemed more protective. Mechanisms of protective effect need to be studied in future studies. 
